Sign in
4

Changes in Ownership

Atara Biotherapeutics, Inc. Filed Acc 0001209191-18-030724

EVP & Chief R & QA Officer sold 4,647 shares at an average $46.06 ($214,026)

  • EVP & Chief R & QA Officer acquired 4,808 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
Clark Mitchall G. EVP & Chief R & QA Officer 2018-05-15 Option exercise +4,808 138,479 D
Clark Mitchall G. EVP & Chief R & QA Officer 2018-05-16 Sale −4,347 $46.04 $200,136 134,132 D
Clark Mitchall G. EVP & Chief R & QA Officer 2018-05-16 Sale −300 $46.30 $13,890 133,832 D
Derivatives
Clark Mitchall G. EVP & Chief R & QA Officer 2018-05-15 Option exercise · Restricted Stock Units −4,808 0 D
Open-market sales · 4,647 sh · avg $46.06 · $214,026
Loading xslF345X03/doc4.xml…